<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vitamin B and its derivatives for diabetic kidney disease - Raval, AD - 2015 | Cochrane Library</title> <meta content="Vitamin B and its derivatives for diabetic kidney disease - Raval, AD - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009403.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vitamin B and its derivatives for diabetic kidney disease - Raval, AD - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009403.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009403.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Vitamin B and its derivatives for diabetic kidney disease" name="citation_title"/> <meta content="Amit D Raval" name="citation_author"/> <meta content="School of Pharmacy West Virginia University" name="citation_author_institution"/> <meta content="amitravalwaves@gmail.com" name="citation_author_email"/> <meta content="Divyesh Thakker" name="citation_author"/> <meta content="Shrimati Kaumudiniben Health Outcome Research Group (SKHORG)" name="citation_author_institution"/> <meta content="Arohi N Rangoonwala" name="citation_author"/> <meta content="Shrimati Kaumudiniben Health Outcome Research Group (SKHORG)" name="citation_author_institution"/> <meta content="Deval Gor" name="citation_author"/> <meta content="University of Illinois at Chicago" name="citation_author_institution"/> <meta content="Rama Walia" name="citation_author"/> <meta content="Post Graduate Institute of Medical Education and Research (PGIMER)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD009403.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/01/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009403.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009403.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009403.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Albuminuria [drug therapy]; Diabetic Nephropathies [*drug therapy]; Folic Acid [therapeutic use]; Pyridoxamine [therapeutic use]; Randomized Controlled Trials as Topic; Selection Bias; Thiamine [analogs &amp; derivatives, therapeutic use]; Vitamin B 12 [therapeutic use]; Vitamin B 6 [therapeutic use]; Vitamin B Complex [adverse effects, *therapeutic use]; Vitamins [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009403.pub2&amp;doi=10.1002/14651858.CD009403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="77cjsSG8";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009403\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009403\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","ja","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009403.pub2",title:"Vitamin B and its derivatives for diabetic kidney disease",firstPublishedDate:"Jan 12, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009403.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009403.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009403.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009403.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009403.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009403.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009403.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009403.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009403.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009403.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4251 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009403.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/full#CD009403-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/full#CD009403-sec-0102"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/full#CD009403-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/full#CD009403-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/full#CD009403-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/full#CD009403-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/full#CD009403-sec-0096"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/appendices#CD009403-sec-0107"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/table_n/CD009403StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/table_n/CD009403StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vitamin B and its derivatives for diabetic kidney disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/information#CD009403-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Amit D Raval</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/information#CD009403-cr-0003">Divyesh Thakker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/information#CD009403-cr-0004">Arohi N Rangoonwala</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/information#CD009403-cr-0005">Deval Gor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009403.pub2/information#CD009403-cr-0006">Rama Walia</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/information/en#CD009403-sec-0112">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 January 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009403.pub2">https://doi.org/10.1002/14651858.CD009403.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009403-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009403-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009403-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009403-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD009403-abs-0002">日本語</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009403-abs-0001" lang="en"> <section id="CD009403-sec-0001"> <h3 class="title" id="CD009403-sec-0001">Background</h3> <p>Diabetes is a leading cause of end‐stage kidney disease (ESKD) mainly due to development and progression of diabetic kidney disease (DKD). In absence of definitive treatments of DKD, small studies showed that vitamin B may help in delaying progression of DKD by inhibiting vascular inflammation and endothelial cell damage. Hence, it could be beneficial as a treatment option for DKD. </p> </section> <section id="CD009403-sec-0002"> <h3 class="title" id="CD009403-sec-0002">Objectives</h3> <p>To assess the benefits and harms of vitamin B and its derivatives in patients with DKD. </p> </section> <section id="CD009403-sec-0003"> <h3 class="title" id="CD009403-sec-0003">Search methods</h3> <p>We searched the Cochrane Renal Group's Specialised Register to 29 October 2012 through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. </p> </section> <section id="CD009403-sec-0004"> <h3 class="title" id="CD009403-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials comparing vitamin B or its derivatives, or both with placebo, no treatment or active treatment in patients with DKD. We excluded studies comparing vitamin B or its derivatives, or both among patients with pre‐existing ESKD. </p> </section> <section id="CD009403-sec-0005"> <h3 class="title" id="CD009403-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed study eligibility, risk of bias and extracted data. Results were reported as risk ratio (RR) or risk differences (RD) with 95% confidence intervals (CI) for dichotomous outcomes and mean difference (MD) with 95% CI for continuous outcomes. Statistical analyses were performed using the random‐effects model. </p> </section> <section id="CD009403-sec-0006"> <h3 class="title" id="CD009403-sec-0006">Main results</h3> <p>Nine studies compared 1354 participants randomised to either vitamin B or its derivatives with placebo or active control were identified. A total of 1102 participants were randomised to single vitamin B derivatives, placebo or active control in eight studies, and 252 participants randomised to multiple vitamin B derivatives or placebo. Monotherapy included different dose of pyridoxamine (four studies), benfotiamine (1), folic acid (1), thiamine (1), and vitamin B<sub>12</sub> (1) while combination therapy included folic acid, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub> in one study. Treatment duration ranged from two to 36 months. Selection bias was unclear in three studies and low in the remaining six studies. Two studies reported blinding of patient, caregiver and observer and were at low risk of performance and detection bias, two studies were at high risk bias, and five studies were unclear. Attrition bias was high in one study, unclear in one study and low in seven studies. Reporting bias was high in one study, unclear in one study, and low in the remaining seven studies. Four studies funded by pharmaceutical companies were judged to be at high risk bias, three were at low risk of bias, and two were unclear. </p> <p>Only a single study reported a reduction in albuminuria with thiamine compared to placebo, while second study reported reduction in glomerular filtration rate (GFR) following use of combination therapy. No significant difference in the risk of all‐cause mortality with pyridoxamine or combination therapy was reported. None of the vitamin B derivatives used either alone or in combination improved kidney function: increased in creatinine clearance, improved the GFR; neither were effective in controlling blood pressure significantly compared to placebo or active control. One study reported a significant median reduction in urinary albumin excretion with thiamine treatment compared to placebo. No significant difference was found between vitamin B combination therapy and control group for serious adverse events, or one or more adverse event per patient. Vitamin B therapy was reported to well‐tolerated with mild side effects in studies with treatment duration of more than six months. Studies of less than six months duration did not explicitly report adverse events; they reported that the drugs were well‐tolerated without any serious drug related adverse events. None of the included studies reported cardiovascular death, progression from macroalbuminuria to ESKD, progression from microalbuminuria to macroalbuminuria, regression from microalbuminuria to normoalbuminuria, doubling of SCr, and quality of life. We were not able to perform subgroup or sensitivity analyses or assess publication bias due to insufficient data. </p> </section> <section id="CD009403-sec-0007"> <h3 class="title" id="CD009403-sec-0007">Authors' conclusions</h3> <p>There is an absence of evidence to recommend the use of vitamin B therapy alone or combination for delaying progression of DKD. Thiamine was found to be beneficial for reduction in albuminuria in a single study; however, there was lack of any improvement in kidney function or blood pressure following the use of vitamin B preparations used alone or in combination. These findings require further confirmation given the limitations of the small number and poor quality of the available studies. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009403-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009403-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009403-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009403-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009403-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009403-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD009403-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009403-abs-0006">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009403-abs-0004" lang="en"> <h3>Vitamin B and its derivatives for diabetic kidney disease</h3> <p>Diabetic kidney disease (DKD) is a disorder which results in excessive protein, mainly albumin, loss in urine. DKD is a major cause of kidney failure and cardiovascular disease in patients with diabetes. Although vitamin B is commonly used in DKD, its effects are unclear. This review included nine studies with a total of 1354 participants. One study reported improvement in urinary albumin levels following use of thiamine. None of the other studies reported improvement in kidney function or reduction in urinary albumin excretion after two to 36 months monotherapy with vitamin B therapy. Vitamin B therapy was reported to well‐tolerated with mild side effects in studies with treatment duration of more than six months. Studies of less than six months duration did not explicitly report adverse events; they reported that the drugs were well‐tolerated without any serious drug related adverse events. All these findings require confirmation in larger studies before they can be accepted as definite. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009403-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009403-sec-0102">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009403-sec-0143">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009403-sec-0102"></div> <h3 class="title" id="CD009403-sec-0103">Implications for practice</h3> <section id="CD009403-sec-0103"> <p>Currently, there is an absence of evidence to recommend the use of vitamin B therapy alone or combination for delaying the progression of DKD. Thiamine was found to be beneficial in reduction in albuminuria in a single study; there was however a lack of any improvement in kidney functions, and blood pressure following the use of vitamin B preparations alone or in combination. These findings require further confirmation given the limitations of small number and poor quality of the available studies. </p> </section> <h3 class="title" id="CD009403-sec-0104">Implications for research</h3> <section id="CD009403-sec-0104"> <p>There is a lack of evidence of short‐term or long‐term benefits of vitamin B compared to placebo or losartan on clinical and biochemical outcomes. There were several limitations of available evidence: small number of studies with poor design; the duration of treatment and the period of observation were too short in some of the studies to detect therapeutic changes; and confounding bias with the use of dietary or fortified sources of vitamin B. In addition, the doses of vitamin B were higher than the recommended daily allowance in all included studies (recommended daily allowance: thiamine (1 mg/d), folate (400 μg/d), vitamin B<sub>12</sub> (2.4 μg/d)). It is not known whether the adequate dose for treatment approximates or is higher than the recommended daily allowance for specific types of vitamin B. Experimental studies showed that a high dose of vitamin B therapy may delay the progression of kidney impairment. Hence, there is a need for selection of optimum dosage regimens of different vitamin B preparation for delaying progression of kidney impairment in patients. In future, high quality RCTs are needed to establish efficacy and safety profile of vitamin B therapy especially treatment used in addition to the first line treatment. Studies should specify the rationale for selecting a particular vitamin B derivative and dose combinations for different stages of DKD. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009403-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009403-sec-0022">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009403-sec-0120">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD009403-sec-0022"></div> <section id="CD009403-sec-0023"> <h3 class="title" id="CD009403-sec-0023">Description of the condition</h3> <p>Diabetic kidney disease (DKD) ‐ also known as diabetic nephropathy ‐ is a common complication that occurs in patients with both type 1 and type 2 diabetes mellitus (DM) (<a href="./references#CD009403-bbs2-0106" title="MarshallSM . Recent advances in diabetic nephropathy. Postgraduate Medical Journal2004;80(949):624‐33. [MEDLINE: 15537844] ">Marshall 2004</a>; <a href="./references#CD009403-bbs2-0109" title="MogensenCE . Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin‐dependent diabetes mellitus patients. Journal of Diabetes &amp; its Complications1995;9(4):337‐49. [MEDLINE: 8573761] ">Mogensen 1995</a>; <a href="./references#CD009403-bbs2-0130" title="ValkEJ , BruijnJA , BajemaIM . Diabetic nephropathy in humans: pathologic diversity. Current Opinion in Nephrology &amp; Hypertension2011;20(3):285‐9. [MEDLINE: 21422920] ">Valk 2011</a>). DKD is characterised by persistent positive albumin excretion in urine. The early stage of microalbuminuria is often referred as incipient nephropathy (urinary albumin excretion (UAE) &gt; 30 mg/24 h) and can progress to macroalbuminuria (UAE &gt; 300 mg/24 h) (overt kidney disease) in the absence of other kidney disease. Glomerular filtration rate (GFR) impairment and end‐stage kidney disease (ESKD) are markers of late stage DKD. Patients with DKD types 1 and 2 share similar prognostic patterns (<a href="./references#CD009403-bbs2-0109" title="MogensenCE . Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin‐dependent diabetes mellitus patients. Journal of Diabetes &amp; its Complications1995;9(4):337‐49. [MEDLINE: 8573761] ">Mogensen 1995</a>; <a href="./references#CD009403-bbs2-0110" title="MogensenCE . Drug treatment for hypertensive patients in special situations: diabetes and hypertension. Clinical &amp; Experimental Hypertension (New York)1999;21(5‐6):895‐906. [PUBMED: 10423111] ">Mogensen 1999</a>). DKD occurs in approximately 20% to 50% of patients with types 1 and 2 diabetes within 20 to 25 years of diabetes onset (<a href="./references#CD009403-bbs2-0075" title="BloomgardenZT . Diabetic nephropathy. Diabetes Care2008;31(4):823‐7. [MEDLINE: 18375432] ">Bloomgarden 2008</a>; <a href="./references#CD009403-bbs2-0085" title="DronavalliS , DukaI , BakrisGL . The pathogenesis of diabetic nephropathy. Nature Clinical Practice Endocrinology &amp; Metabolism2008;4(8):444‐52. [MEDLINE: 18607402] ">Dronavalli 2008</a>; <a href="./references#CD009403-bbs2-0093" title="GrossJL , deAzevedoMJ , SilveiroSP , CananiLH , CaramoriML , ZelmanovitzT . Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care2005;28(1):164‐76. [MEDLINE: 15616252] ">Gross 2005</a>; <a href="./references#CD009403-bbs2-0106" title="MarshallSM . Recent advances in diabetic nephropathy. Postgraduate Medical Journal2004;80(949):624‐33. [MEDLINE: 15537844] ">Marshall 2004</a>; <a href="./references#CD009403-bbs2-0120" title="RitzE , OrthSR . Nephropathy in patients with type 2 diabetes mellitus. New England Journal of Medicine1999;341(15):1127‐33. [MEDLINE: 10511612] ">Ritz 1999</a>). Progression from microalbuminuria to macroalbuminuria occurs in 40% to 60% of patients with types 1 and 2 DM over 5 to 10 years of period (<a href="./references#CD009403-bbs2-0075" title="BloomgardenZT . Diabetic nephropathy. Diabetes Care2008;31(4):823‐7. [MEDLINE: 18375432] ">Bloomgarden 2008</a>). Between 20% and 40% of patients with DKD progress to ESKD, and there is a high risk of death from associated coronary artery disease and other cardiovascular causes with DKD (<a href="./references#CD009403-bbs2-0084" title="DinneenSF , GersteinHC . The association of microalbuminuria and mortality in non‐insulin‐dependent diabetes mellitus. A systematic overview of the literature. Archives of Internal Medicine1997;157(13):1413‐8. [MEDLINE: 9224218] ">Dinneen 1997</a>; <a href="./references#CD009403-bbs2-0090" title="GallMA , NielsenFS , SmidtUM , ParvingHH . The course of kidney function in type 2 (non‐insulin‐dependent) diabetic patients with diabetic nephropathy. Diabetologia1993;36(10):1071‐8. [MEDLINE: 8243857] ">Gall 1993</a>). The risk of cardiovascular disease increases progressively as albuminuria levels escalate and GFR decreases (<a href="./references#CD009403-bbs2-0065" title="AdlerAI , StevensRJ , ManleySE , BilousRW , CullCA , HolmanRR , et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney international2003;63(1):225‐32. [MEDLINE: 12472787] ">Adler 2003</a>; <a href="./references#CD009403-bbs2-0108" title="MiettinenH , HaffnerSM , LehtoS , RonnemaaT , PyoralaK , LaaksoM . Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non‐insulin‐dependent diabetic subjects. Stroke1996;27(11):2033‐9. [MEDLINE: 8898811] ">Miettinen 1996</a>; <a href="./references#CD009403-bbs2-0131" title="ValmadridCT , KleinR , MossSE , KleinBE . The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older‐onset diabetes mellitus. Archives of Internal Medicine2000;160(8):1093‐100. [MEDLINE: 10789601] ">Valmadrid 2000</a>). Cardiovascular disease is a major cause of death in patients with ESKD (<a href="./references#CD009403-bbs2-0104" title="LevinA . Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Seminars in Dialysis2003;16(2):101‐5. [MEDLINE: 12641872] ">Levin 2003</a>) and therefore imposes a substantial burden in terms of morbidity, and mortality. DKD management strategies should be directed towards limiting progression to ESKD and reducing mortality. </p> <p>Risk factors associated with development of DKD include sustained hyperglycaemia and hypertension (<a href="./references#CD009403-bbs2-0064" title="AdlerAI , StrattonIM , NeilHA , YudkinJS , MatthewsDR , CullCA , et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ2000;321(7258):412‐9. [MEDLINE: 10938049] ">Adler 2000</a>; <a href="./references#CD009403-bbs2-0088" title="FiorettoP , SteffesMW , SutherlandDE , GoetzFC , MauerM . Reversal of lesions of diabetic nephropathy after pancreas transplantation. New England journal of Medicine1998;339(2):69‐75. [MEDLINE: 9654536] ">Fioretto 1998</a>; <a href="./references#CD009403-bbs2-0091" title="GallMA , HougaardP , Borch‐JohnsenK , ParvingHH . Risk factors for development of incipient and overt diabetic nephropathy in patients with non‐insulin dependent diabetes mellitus: prospective, observational study. BMJ1997;314(7083):783‐8. [MEDLINE: 9080995] ">Gall 1997</a>; <a href="./references#CD009403-bbs2-0107" title="Anonymous . Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven‐year prospective study. The Microalbuminuria Collaborative Study Group. Diabetic Medicine1999;16(11):918‐25. [MEDLINE: 10588521] ">MCSG 1999</a>; <a href="./references#CD009403-bbs2-0117" title="RavidM , BroshD , Ravid‐SafranD , LevyZ , RachmaniR . Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Archives of Internal Medicine1998;158(9):998‐1004. [MEDLINE: 9588433] ">Ravid 1998</a>; <a href="./references#CD009403-bbs2-0125" title="StrattonIM , AdlerAI , NeilHA , MatthewsDR , ManleySE , CullCA , et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000;321(7258):405‐12. [MEDLINE: 10938048] ">Stratton 2000</a>); glomerular hyperfiltration (<a href="./references#CD009403-bbs2-0079" title="CaramoriML , GrossJL , PecisM , deAzevedoMJ . Glomerular filtration rate, urinary albumin excretion rate, and blood pressure changes in normoalbuminuric normotensive type 1 diabetic patients: an 8‐year follow‐up study. Diabetes Care1999;22(9):1512‐6. [MEDLINE: 10480518] ">Caramori 1999</a>; <a href="./references#CD009403-bbs2-0083" title="DahlquistG , StattinEL , RudbergS . Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long‐term follow‐up study of childhood onset type‐1 diabetic patients. Nephrology Dialysis Transplantation2001;16(7):1382‐6. [MEDLINE: 11427629] ">Dahlquist 2001</a>; <a href="./references#CD009403-bbs2-0124" title="SilveiroSP , daCostaLA , BeckMO , GrossJL . Urinary albumin excretion rate and glomerular filtration rate in single‐kidney type 2 diabetic patients. Diabetes Care1998;21(9):1521‐4. [MEDLINE: 9727902] ">Silveiro 1998</a>); smoking (<a href="./references#CD009403-bbs2-0099" title="HovindP , RossingP , TarnowL , ParvingHH . Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care2003;26(3):911‐6. [MEDLINE: 12610058] ">Hovind 2003</a>; <a href="./references#CD009403-bbs2-0122" title="SawickiPT , DidjurgeitU , MuhlhauserI , BenderR , HeinemannL , BergerM . Smoking is associated with progression of diabetic nephropathy. Diabetes Care1994;17(2):126‐31. [MEDLINE: 8137682] ">Sawicki 1994</a>); dyslipidaemia (<a href="./references#CD009403-bbs2-0069" title="AppelGB , RadhakrishnanJ , AvramMM , DeFronzoRA , Escobar‐JimenezF , CamposMM , et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care2003;26(5):1402‐7. [MEDLINE: 12716796] ">Appel 2003</a>; <a href="./references#CD009403-bbs2-0080" title="ChaturvediN , FullerJH , TaskinenMR , EURODIAB PCS Group. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care2001;24(12):2071‐7. [MEDLINE: 11723085] ">Chaturvedi 2001</a>; <a href="./references#CD009403-bbs2-0091" title="GallMA , HougaardP , Borch‐JohnsenK , ParvingHH . Risk factors for development of incipient and overt diabetic nephropathy in patients with non‐insulin dependent diabetes mellitus: prospective, observational study. BMJ1997;314(7083):783‐8. [MEDLINE: 9080995] ">Gall 1997</a>; <a href="./references#CD009403-bbs2-0117" title="RavidM , BroshD , Ravid‐SafranD , LevyZ , RachmaniR . Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Archives of Internal Medicine1998;158(9):998‐1004. [MEDLINE: 9588433] ">Ravid 1998</a>); proteinuria levels (<a href="./references#CD009403-bbs2-0121" title="RuggenentiP , RemuzziG . Nephropathy of type‐2 diabetes mellitus. Journal of the American Society of Nephrology1998;9(11):2157‐69. [MEDLINE: 9808106] ">Ruggenenti 1998</a>; <a href="./references#CD009403-bbs2-0118" title="RemuzziG , RuggenentiP , BenigniA . Understanding the nature of renal disease progression. Kidney international1997;51(1):2‐15. [MEDLINE: 8995712] ">Remuzzi 1997</a>); and dietary factors, such as the amount and source of protein (<a href="./references#CD009403-bbs2-0111" title="MollstenAV , DahlquistGG , StattinEL , RudbergS . Higher intakes of fish protein are related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients. Diabetes Care2001;24(5):805‐10. [MEDLINE: 11347734] ">Mollsten 2001</a>; <a href="./references#CD009403-bbs2-0115" title="PecisM , deAzevedoMJ , GrossJL . Chicken and fish diet reduces glomerular hyperfiltration in IDDM patients. Diabetes Care1994;17(7):665‐72. [MEDLINE: 7924775] ">Pecis 1994</a>; <a href="./references#CD009403-bbs2-0129" title="ToellerM , BuykenA , HeitkampG , BramswigS , MannJ , MilneR , et al. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia1997;40(10):1219‐26. [MEDLINE: 9349605] ">Toeller 1997</a>) and fat (<a href="./references#CD009403-bbs2-0119" title="RileyMD , DwyerT . Microalbuminuria is positively associated with usual dietary saturated fat intake and negatively associated with usual dietary protein intake in people with insulin‐dependent diabetes mellitus. American Journal of Clinical Nutrition1998;67(1):50‐7. [MEDLINE: 9440375] ">Riley 1998</a>) in the diet as putative risk factors. Multidimensional management is therefore required for DKD to control risk factors and inhibit pathogenic pathways. Despite availability of effective therapies that can reduce progression of DKD, such as angiotensin‐converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), prostaglandin E1, and aldosterone antagonists, many patients with DKD develop ESKD (<a href="./references#CD009403-bbs2-0076" title="BolignanoD , PalmerSC , NavaneethanSD , StrippoliGF . Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD007004.pub3] ">Bolignano 2014</a>; <a href="./references#CD009403-bbs2-0133" title="WangH , DengJL , YueJ , LiJ , HouYB . Prostaglandin E1 for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews2010, Issue 5. [DOI: 10.1002/14651858.CD006872.pub2] ">Wang 2010</a>). Around 40% of the estimated 21 million patients with diabetes in the United States develop advanced DKD despite optimum treatment (<a href="./references#CD009403-bbs2-0114" title="PalmerAJ , ValentineWJ , ChenR , MehinN , GabrielS , BregmanB , et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrology Dialysis Transplantation2008;23(4):1216‐23. [MEDLINE: 18359872] ">Palmer 2008</a>). More and newer interventions are required to limit the impact of DKD. </p> </section> <section id="CD009403-sec-0024"> <h3 class="title" id="CD009403-sec-0024">Description of the intervention</h3> <p>The B vitamins are a group of eight water‐soluble vitamins that play important roles in cell metabolism. Vitamin B complex contains all eight components: vitamin B<sub>1</sub> (thiamine), vitamin B<sub>2</sub> (riboflavin), vitamin B<sub>3</sub> (niacin or niacinamide), vitamin B<sub>5</sub> (pantothenic acid), vitamin B<sub>6</sub> (pyridoxine, pyridoxal, or pyridoxamine, or pyridoxine hydrochloride), vitamin B<sub>7</sub> (biotin), vitamin B<sub>9</sub> (folic acid) and vitamin B<sub>12</sub>. Vitamin B<sub>12</sub> has several congeners: cyanocobalamin, hydroxocobalamin, methylcobalamin, and 5’‐deoxyadenosylcobalamin. Each vitamin B complex component has an individual structure and performs unique function in the human body. Vitamins B<sub>1</sub>, B<sub>2</sub>, B<sub>3</sub>, and biotin participate in different aspects of energy production; vitamin B<sub>6</sub> is essential for amino acid metabolism, and vitamin B<sub>12</sub> and folic acid facilitate steps required for cell division. Thiamine is required for normal functioning of the heart, muscles, and nerves, and its intake is beneficial in the treatment of certain metabolic disorders (<a href="https://mail.google.com/mail/html/compose/static_files/Malecka%202006" target="_blank">Malecka 2006</a>; <a href="./references#CD009403-bbs2-0126" title="ThornalleyPJ . The potential role of thiamine (vitamin B1) in diabetic complications. Current Diabetes Reviews2005;1(3):287‐98. [MEDLINE: 18220605] ">Thornalley 2005</a>). Benfotiamine is a derivative of thiamine monophosphate which is better absorbed after oral administration than the water‐soluble thiamine salts resulting in higher levels of the active compound in blood and tissues (<a href="./references#CD009403-bbs2-0123" title="SchreebKH , FreudenthalerS , VormfeldeSV , Gundert‐RemyU , GleiterCH . Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate. European Journal of Clinical Pharmacology1997; Vol. 52, issue 4:319‐20. [MEDLINE: 9248773] ">Schreeb 1997</a>; <a href="./references#CD009403-bbs2-0136" title="WuS , RenJ . Benfotiamine alleviates diabetes‐induced cerebral oxidative damage independent of advanced glycation end‐product, tissue factor and TNF‐alpha. Neuroscience Letters2006;394(2):158‐62. [MEDLINE: 16260089] ">Wu 2006</a>). Requirements for components of the vitamin B complex vary considerably ‐ from 3 μg/d for vitamin B<sub>12</sub> to 18 mg/d for vitamin B<sub>3</sub> in adult males. </p> </section> <section id="CD009403-sec-0025"> <h3 class="title" id="CD009403-sec-0025">How the intervention might work</h3> <p>Hyperglycaemia is a major risk factor for DKD. It leads a cascade of biochemical reactions that are ultimately responsible for DKD. High cytosolic glucose concentration leads to metabolic dysfunction by over expression of glucose transporter‐1 (GLUT1) in renal mesangial cells. These involve activation of the protein kinase C (PKC) (<a href="./references#CD009403-bbs2-0070" title="AyoSH , RadnikR , GaroniJA , TroyerDA , KreisbergJI . High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. American Journal of Physiology1991;261(4 Pt 2):F571‐7. [MEDLINE: 1928372] ">Ayo 1991</a>) hexosamine pathway, and polyol pathways (<a href="./references#CD009403-bbs2-0081" title="ChungSS , HoEC , LamKS , ChungSK . Contribution of polyol pathway to diabetes‐induced oxidative stress. Journal of the American Society of Nephrology2003;14(8 Suppl 3):S233‐6. [MEDLINE: 12874437] ">Chung 2003</a>); accumulation of triose phosphates (<a href="./references#CD009403-bbs2-0128" title="TiltonRG , BaierLD , HarlowJE , SmithSR , OstrowE , WilliamsonJR . Diabetes‐induced glomerular dysfunction: links to a more reduced cytosolic ratio of NADH/NAD+. Kidney International1992;41(4):778‐88. [MEDLINE: 1513100] ">Tilton 1992</a>); metabolic pseudo hypoxia; mitochondrial dysfunction, oxidative stress (<a href="./references#CD009403-bbs2-0113" title="NishikawaT , EdelsteinD , DuXL , YamagishiS , MatsumuraT , KanedaY , et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature2000;404(6779):787‐90. [MEDLINE: 10783895] ">Nishikawa 2000</a>; <a href="./references#CD009403-bbs2-0137" title="YimMB , YimHS , LeeC , KangSO , ChockPB . Protein glycation: creation of catalytic sites for free radical generation. Annals of the New York Academy of Sciences2001;928:48‐53. [MEDLINE: 11795527] ">Yim 2001</a>) and accumulation of advanced glycation end (AGE) products (<a href="./references#CD009403-bbs2-0078" title="BrownleeM . Biochemistry and molecular cell biology of diabetic complications. Nature2001;414(6865):813‐20. [MEDLINE: 11742414] ">Brownlee 2001</a>; <a href="./references#CD009403-bbs2-0086" title="DuXL , EdelsteinD , RossettiL , FantusIG , GoldbergH , ZiyadehF , et al. Hyperglycemia‐induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor‐1 expression by increasing Sp1 glycosylation. Proceedings of the National Academy of Sciences of the United States of America2000;97(22):12222‐6. [MEDLINE: 11050244] ">Du 2000</a>; <a href="./references#CD009403-bbs2-0096" title="HeiligCW , ConcepcionLA , RiserBL , FreytagSO , ZhuM , CortesP . Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. Journal of Clinical Investigation1995;96(4):1802‐14. [MEDLINE: 7560072] ">Heilig 1995</a>). AGE products accumulate in the kidneys which are centrally involved in AGE product clearance (<a href="./references#CD009403-bbs2-0089" title="ForbesJM , CooperME , OldfieldMD , ThomasMC . Role of advanced glycation end products in diabetic nephropathy. Journal of the American Society of Nephrology2003;14(8 Suppl 3):S254‐8. [MEDLINE: 12874442] ">Forbes 2003</a>). There is a strong correlation between AGE product accumulation and the presence and severity of DKD (<a href="./references#CD009403-bbs2-0112" title="MonnierVM , BautistaO , KennyD , SellDR , FogartyJ , DahmsW , et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long‐term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes1999;48(4):870‐80. [MEDLINE: 10102706] ">Monnier 1999</a>). High sugar level in cells disrupts normal cellular glucose metabolism resulting in accumulation of super reactive glucose‐metabolic intermediates such as triose phosphates. Excess triose phosphates attack surrounding proteins, lipids and DNA resulting in formation of oxo aldehydes that creates AGE product damage (<a href="./references#CD009403-bbs2-0078" title="BrownleeM . Biochemistry and molecular cell biology of diabetic complications. Nature2001;414(6865):813‐20. [MEDLINE: 11742414] ">Brownlee 2001</a>; <a href="./references#CD009403-bbs2-0126" title="ThornalleyPJ . The potential role of thiamine (vitamin B1) in diabetic complications. Current Diabetes Reviews2005;1(3):287‐98. [MEDLINE: 18220605] ">Thornalley 2005</a>). Accumulation of triose phosphates arising from high cytosolic glucose concentrations trigger biochemical dysfunction in renal cells that ultimately leads to development of DKD (<a href="./references#CD009403-bbs2-0071" title="Babaei‐JadidiR , KarachaliasN , AhmedN , BattahS , ThornalleyPJ . Prevention of incipient diabetic nephropathy by high‐dose thiamine and benfotiamine. Diabetes2003;52(8):2110‐20. [MEDLINE: 12882930] ">Babaei‐Jadidi 2003</a>; <a href="./references#CD009403-bbs2-0113" title="NishikawaT , EdelsteinD , DuXL , YamagishiS , MatsumuraT , KanedaY , et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature2000;404(6779):787‐90. [MEDLINE: 10783895] ">Nishikawa 2000</a>; <a href="./references#CD009403-bbs2-0128" title="TiltonRG , BaierLD , HarlowJE , SmithSR , OstrowE , WilliamsonJR . Diabetes‐induced glomerular dysfunction: links to a more reduced cytosolic ratio of NADH/NAD+. Kidney International1992;41(4):778‐88. [MEDLINE: 1513100] ">Tilton 1992</a>). Preventing triose phosphate accumulation in hyperglycaemia can suppress these pathways and prevent DKD development. </p> <p>Thiamine has been associated with reducing serum and tissue accumulation of AGE products and investigated for its utility in DKD prevention (<a href="./references#CD009403-bbs2-0126" title="ThornalleyPJ . The potential role of thiamine (vitamin B1) in diabetic complications. Current Diabetes Reviews2005;1(3):287‐98. [MEDLINE: 18220605] ">Thornalley 2005</a>). Thiamine pyrophosphate (TPP), an active form of thiamine, has been shown to prevent AGE product formation by inhibiting conversion of Amadori products to AGE products (<a href="./references#CD009403-bbs2-0077" title="BoothAA , KhalifahRG , HudsonBG . Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end‐products: comparison with aminoguanidine. Biochemical &amp; Biophysical Research Communications1996;220(1):113‐9. [MEDLINE: 8602828] ">Booth 1996</a>; <a href="./references#CD009403-bbs2-0092" title="GohSY , CooperME . Clinical review: the role of advanced glycation end products in progression and complications of diabetes. Journal of Clinical Endocrinology &amp; Metabolism2008;93(4):1143‐52. [MEDLINE: 18182449] ">Goh 2008</a>). TPP normalises triose phosphates by activating the reductive pentose phosphate pathway (<a href="./references#CD009403-bbs2-0071" title="Babaei‐JadidiR , KarachaliasN , AhmedN , BattahS , ThornalleyPJ . Prevention of incipient diabetic nephropathy by high‐dose thiamine and benfotiamine. Diabetes2003;52(8):2110‐20. [MEDLINE: 12882930] ">Babaei‐Jadidi 2003</a>). TPP activates an enzyme (transketolase) that shunts excess triose phosphates into a safe alternative pentose phosphate metabolic pathway which prevents formation of AGE products and high sugar‐induced metabolic cellular stress (<a href="./references#CD009403-bbs2-0092" title="GohSY , CooperME . Clinical review: the role of advanced glycation end products in progression and complications of diabetes. Journal of Clinical Endocrinology &amp; Metabolism2008;93(4):1143‐52. [MEDLINE: 18182449] ">Goh 2008</a>; <a href="./references#CD009403-bbs2-0095" title="HatfieldJ . Advanced glycation end‐products (AGEs) in hyperglycemic patients. October 2005. www.jyi.org/issue/review‐advanced‐glycation‐end‐products‐ages‐in‐hyperglycemic‐patients (accessed 23 December 2014). ">Hatfield 2005</a>; <a href="./references#CD009403-bbs2-0100" title="HuijbertsMS , SchaperNC , SchalkwijkCG . Advanced glycation end products and diabetic foot disease. Diabetes/Metabolism Research Reviews2008;24 Suppl 1:S19‐24. [MEDLINE: 18442180] ">Huijberts 2008</a>). This action stimulates conversion of GA3P and fructose‐6‐phosphate (F6P) to ribose‐5‐phosphate (R5P) (<a href="./references#CD009403-bbs2-0071" title="Babaei‐JadidiR , KarachaliasN , AhmedN , BattahS , ThornalleyPJ . Prevention of incipient diabetic nephropathy by high‐dose thiamine and benfotiamine. Diabetes2003;52(8):2110‐20. [MEDLINE: 12882930] ">Babaei‐Jadidi 2003</a>). In pre‐clinical experimental models, high‐dose thiamine and benfotiamine corrected delayed replication; activation of PKC; increased hexosamine and AGE product concentrations; and oxidative stress in capillary and aortal endothelial cells (<a href="./references#CD009403-bbs2-0073" title="BergfeldR , MatsumaraT , DuX , BrownleeM . Benfotiamin prevents the consequences of hyperglycemia induced mitochondrial overproduction of reactive oxygen species and experimental diabetic retinopathy [abstract]. Diabetologia2001;44(Suppl 1):A39. ">Bergfeld 2001</a>; <a href="./references#CD009403-bbs2-0103" title="LaSelvaM , BeltramoE , PagnozziF , BenaE , MolinattiPA , MolinattiGM , et al. Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end‐products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia1996;39(11):1263‐8. [MEDLINE: 8932990] ">La Selva 1996</a>). Benfotiamine blocks three major biochemical pathways that are involved in chronic hyperglycaemia‐induced vascular damage: the hexosamine pathway, AGE formation pathway and diacylglycerol–PKC pathway (<a href="./references#CD009403-bbs2-0094" title="HammesHP , DuX , EdelsteinD , TaguchiT , MatsumuraT , JuQ , et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine2003;9(3):294‐9. [MEDLINE: 12592403] ">Hammes 2003</a>). Benfotiamine has been reported to prevent progression of diabetic complications by increasing tissue levels of thiamine diphosphate and subsequently enhancing transketolase activity (<a href="./references#CD009403-bbs2-0094" title="HammesHP , DuX , EdelsteinD , TaguchiT , MatsumuraT , JuQ , et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine2003;9(3):294‐9. [MEDLINE: 12592403] ">Hammes 2003</a>; <a href="./references#CD009403-bbs2-0132" title="VolvertML , SeyenS , PietteM , EvrardB , GangolfM , PlumierJC , et al. Benfotiamine, a synthetic S‐acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid‐soluble thiamine disulfide derivatives. BMC Pharmacology2008;8:10. [MEDLINE: 18549472] ">Volvert 2008</a>). Supplementation with benfotiamine in patients with DKD has been reported to be responsible for decreased incidence of albuminuria/proteinuria, AGE product accumulation and oxidative stress in renal cells (<a href="./references#CD009403-bbs2-0072" title="BakkerSJ , HeineRJ , GansRO . Thiamine may indirectly act as an antioxidant. Diabetologia1997; Vol. 40, issue 6:741‐2. [MEDLINE: 9222658] ">Bakker 1997</a>; <a href="./references#CD009403-bbs2-0101" title="KarachaliasN , Babaei‐JadidiR , AhmedN , ThornalleyPJ . Accumulation of fructosyl‐lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin‐induced diabetic rats. Biochemical Society Transactions2003;31(Pt 6):1423‐5. [MEDLINE: 14641079] ">Karachalias 2003</a>; <a href="./references#CD009403-bbs2-0127" title="ThornalleyPJ , Babaei‐JadidiR , Al AliH , RabbaniN , AntonysunilA , LarkinJ , et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia2007;50(10):2164‐70. [MEDLINE: 17676306] ">Thornalley 2007</a>). Overall, these actions decrease inflammatory and fibrotic responses to inhibit DKD progression (<a href="./references#CD009403-bbs2-0072" title="BakkerSJ , HeineRJ , GansRO . Thiamine may indirectly act as an antioxidant. Diabetologia1997; Vol. 40, issue 6:741‐2. [MEDLINE: 9222658] ">Bakker 1997</a>; <a href="./references#CD009403-bbs2-0101" title="KarachaliasN , Babaei‐JadidiR , AhmedN , ThornalleyPJ . Accumulation of fructosyl‐lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin‐induced diabetic rats. Biochemical Society Transactions2003;31(Pt 6):1423‐5. [MEDLINE: 14641079] ">Karachalias 2003</a>; <a href="./references#CD009403-bbs2-0127" title="ThornalleyPJ , Babaei‐JadidiR , Al AliH , RabbaniN , AntonysunilA , LarkinJ , et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia2007;50(10):2164‐70. [MEDLINE: 17676306] ">Thornalley 2007</a>). Apart from thiamine, experimental studies have confirmed that pyridoxamine is also a potent inhibitor of AGE product accumulation, and effective in reducing kidney injury in diabetes (<a href="./references#CD009403-bbs2-0068" title="AldersonNL , ChachichME , YoussefNN , BeattieRJ , NachtigalM , ThorpeSR , et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney international2003;63(6):2123‐33. [MEDLINE: 12753299] ">Alderson 2003</a>). </p> </section> <section id="CD009403-sec-0026"> <h3 class="title" id="CD009403-sec-0026">Why it is important to do this review</h3> <p>Evaluating the efficacy of vitamin B and its derivatives, alone or in combinations, for inhibiting progression of DKD and reducing mortality may provide additional options to current treatment pathways for patients with DKD. There is a substantial body of published clinical studies, and many ongoing investigations, in the intervention of interest. Currently, there are no health technology assessment reviews or systematic reviews assessing vitamin B or its derivatives, or both for DKD. The scope of the current review is to identify and aggregate good quality evidence on vitamin B or its derivatives, or both for DKD with the major focus on core clinical and patient‐related outcomes ‐ as these aspects are important contributors to the strength of recommendations for all therapies and also the use of vitamin B preparations in DKD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009403-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009403-sec-0027">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009403-sec-0125">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009403-sec-0027"></div> <p>We assessed the benefits and harms of vitamin B and its derivatives in patients with DKD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009403-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009403-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009403-sec-0126">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009403-sec-0028"></div> <section id="CD009403-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009403-sec-0030"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) evaluating benefits and harms of vitamin B or its derivatives, or both in the patients with DKD. </p> </section> <section id="CD009403-sec-0031"> <h4 class="title">Types of participants</h4> <section id="CD009403-sec-0032"> <h5 class="title">Inclusion criteria</h5> <p>We included studies conducted in patients with type 1 and type 2 DKD. To consistently capture changes in classification and diagnostic criteria for DM over time, we included studies that assigned standard criteria that were valid at study outset (e.g. <a href="./references#CD009403-bbs2-0061" title="GavinJRIII , AlbertiKG , DavidsonMB , DeFronzoRA , DrashA , GabbeSG , et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care1999;22(1 Suppl):S5‐19. [EMBASE: 1999016853] ">ADA 1999</a>; <a href="./references#CD009403-bbs2-0062" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2008. Diabetes Care2008;31 Suppl 1:S12‐54. [MEDLINE: 18165335] ">ADA 2008</a>; <a href="./references#CD009403-bbs2-0063" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2010. Diabetes Care2010;33 Suppl 1:S11‐61. [MEDLINE: 20042772] ">ADA 2010</a>; <a href="./references#CD009403-bbs2-0067" title="AlbertiKM , ZimmetPZ . Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine1998;15(7):539‐53. [MEDLINE: 9686693] ">Alberti 1998</a>; <a href="./references#CD009403-bbs2-0134" title="WHO Expert Committee on Diabetes Mellitus. World Health Organization. Second report. Technical Report Series 646. 1980. whqlibdoc.who.int/trs/WHO_TRS_646.pdf (accessed 12 December 2014). ">WHO 1980</a>; <a href="./references#CD009403-bbs2-0135" title="WHO Expert Committee on Diabetes Mellitus. Diabetes mellitus. World Health Organization Technical Report Series 727. 1985. whqlibdoc.who.int/trs/WHO_TRS_727.pdf (accessed 12 December 2014). ">WHO 1985</a>). Ideally, diagnostic criteria should have been described. Further, diagnostic criteria for DKD should be mentioned clearly and should adhere to diagnosis provided by the American Diabetes Association (ADA) (<a href="./references#CD009403-bbs2-0061" title="GavinJRIII , AlbertiKG , DavidsonMB , DeFronzoRA , DrashA , GabbeSG , et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care1999;22(1 Suppl):S5‐19. [EMBASE: 1999016853] ">ADA 1999</a>; <a href="./references#CD009403-bbs2-0062" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2008. Diabetes Care2008;31 Suppl 1:S12‐54. [MEDLINE: 18165335] ">ADA 2008</a>; <a href="./references#CD009403-bbs2-0063" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2010. Diabetes Care2010;33 Suppl 1:S11‐61. [MEDLINE: 20042772] ">ADA 2010</a>; <a href="./references#CD009403-bbs2-0102" title="KDOQI . KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. American Journal of Kidney Diseases2007;49(2 Suppl 2):S12‐154. [MEDLINE: 17276798] ">KDOQI 2007</a>) and other standard guideline. If necessary, we used authors' definition of DM and DKD. We planned to investigate diagnostic criteria used for diabetes and DKD in sensitivity analysis. </p> </section> <section id="CD009403-sec-0033"> <h5 class="title">Exclusion criteria</h5> <p>We excluded studies in patients with kidney injury due to diseases other than diabetes, and types of diabetes other than type 1 or type 2 diabetes (i.e. gestational diabetes) or patients with final stage DKD or ESKD (GFR &lt; 10 mL/min or requirement for renal replacement therapy). </p> </section> </section> <section id="CD009403-sec-0034"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD009403-list-0001"> <li> <p>Vitamin B, its derivative preparations, or both versus placebo</p> </li> <li> <p>Vitamin B, its derivative preparations, or both plus other drugs versus other drugs (ACEIs, ARBs, calcium channel blockers (CCBs)) </p> </li> <li> <p>Vitamin B, its derivative preparations, or both versus other drugs (ACEIs, ARBs, CCBs).</p> </li> </ul> </p> </section> <section id="CD009403-sec-0035"> <h4 class="title">Types of outcome measures</h4> <section id="CD009403-sec-0036"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009403-list-0002"> <li> <p>All‐cause mortality</p> </li> <li> <p>Cardiovascular mortality.</p> </li> </ul> </p> </section> <section id="CD009403-sec-0037"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009403-list-0003"> <li> <p>Progression from macroalbuminuria to ESKD</p> </li> <li> <p>Progression from microalbuminuria to macroalbuminuria</p> </li> <li> <p>Regression from microalbuminuria to normoalbuminuria</p> </li> <li> <p>Kidney function measures (creatinine clearance (CrCl), GFR, doubling of serum creatinine (SCr), SCr, proteinuria, dialysis) </p> </li> <li> <p>Blood pressure (systolic (SBP); diastolic (DBP))</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Adverse events.</p> </li> </ul> </p> <section id="CD009403-sec-0038"> <h6 class="title">Timing of outcome measurement</h6> <p>We assessed outcomes in the short‐term (≥ 12 weeks to &lt; 18 weeks), medium‐term (≥ 18 weeks to &lt; 52 weeks) and long‐term (≥ 52 weeks). Data from long term extension studies of RCTs was considered only if participants were maintained the same sequence allocation as in the initial feeder study. </p> </section> </section> </section> </section> <section id="CD009403-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009403-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Renal Group's Specialised Register (to 29 October 2012) through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. The Cochrane Renal Group’s Specialised Register contains studies identified from the following sources. </p> <p> <ol id="CD009403-list-0004"> <li> <p>Quarterly searches of the Cochrane Central Register of Controlled Trials CENTRAL</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of renal‐related journals and the proceedings of major renal conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected renal journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies as well as a list of handsearched journals, conference proceedings and current awareness alerts are available in the Specialised Register section of information about the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Renal Group</a>. </p> <p>See <a href="./appendices#CD009403-sec-0108">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD009403-sec-0041"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD009403-list-0005"> <li> <p>Reference lists of clinical practice guidelines, review articles and relevant studies.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD009403-sec-0042"> <h3 class="title" id="CD009403-sec-0042">Data collection and analysis</h3> <section id="CD009403-sec-0043"> <h4 class="title">Selection of studies</h4> <p>The search strategy as described was used to obtain titles and abstracts of studies with relevance to the review. The titles and abstracts were screened independently by two authors who discarded studies that were not applicable; however, studies and reviews that may include relevant data or information on studies were retained initially. The same two authors independently assessed retrieved abstracts, and if necessary the full text of these studies to determine if they satisfy the inclusion criteria. Interrater agreement for selection of potentially relevant studies was measured using the kappa statistic (<a href="./references#CD009403-bbs2-0082" title="CohenJ . A coefficient of agreement for nominal scales. Educational &amp; Psychological Measurement1960;20:37‐46. ">Cohen 1960</a>). Disagreements were resolved by consensus between authors. A third author arbitrated if consensus could not be achieved. An adapted PRISMA flowchart illustrated the study selection process (<a href="./references#CD009403-bbs2-0105" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine/Public Library of Science1999;6(7):e1000100. [MEDLINE: 19621070] ">Liberati 2009</a>). </p> </section> <section id="CD009403-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non‐English language journals were to be translated before assessment. Where more than one publication of one study existed, reports be grouped together and the publication with the most complete data was used in the analyses. When relevant outcomes were only published in earlier versions these data were used. Any discrepancies between published versions were to be highlighted. </p> </section> <section id="CD009403-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD009403-bbs2-0098" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated February 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD009403-sec-0109">Appendix 2</a>). </p> <p> <ul id="CD009403-list-0006"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? </p> <ul id="CD009403-list-0007"> <li> <p>Participants and personnel</p> </li> <li> <p>Outcome assessors</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD009403-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>Results were expressed as risk ratio (RR) with 95% confidence intervals (CI) for dichotomous outcomes, such as death. Mean differences (MD) was calculated where continuous scales of measurement were used to assess the effects of treatment (blood pressure, CrCl, UAE, SCr, quality of life), or the standardised mean difference (SMD) if different scales were used. Time‐to‐event outcomes (such as time to development of macrovascular disease or ESKD) were to be expressed as hazard ratios (HR) with 95% CI. Adverse effects were tabulated and assessed with descriptive techniques, as they are likely to be different for the various agents used. Where possible, the RR with 95% CI was calculated for each adverse effect, either compared to no treatment or to another agent. </p> </section> <section id="CD009403-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>We took into account the level at which randomisation occurred, such as cross‐over studies, cluster‐randomised studies and multiple observations for the same outcome (<a href="./references#CD009403-bbs2-0098" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated February 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>)<i>.</i> </p> </section> <section id="CD009403-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>We obtained relevant missing data from some of included the study authors upon sending e‐mail to them. We investigated attrition rates (drop‐outs, loss to follow‐up and withdrawals) and critically appraise missing data issues and imputation methods (such as last‐observation‐carried‐forward) (<a href="./references#CD009403-bbs2-0098" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated February 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>)<i>.</i> </p> </section> <section id="CD009403-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi² test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<a href="./references#CD009403-bbs2-0097" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity, respectively. </p> </section> <section id="CD009403-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>There were insufficient studies to assess potential existence of study bias using funnel plot. </p> </section> <section id="CD009403-sec-0051"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model but the fixed‐effect model was also used to ensure robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD009403-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was conducted to explore possible sources of heterogeneity, such as participants, interventions and study quality. Heterogeneity among participants may be related to age and renal pathology. Heterogeneity in treatments may be related to prior agents used and dose and duration of therapy. We planned to perform subgroup analyses as one of the primary outcome parameters demonstrated statistically significant differences between intervention groups. </p> <p>Due to insufficient studies, we were not able to conduct subgroup analysis as planned for primary outcomes based on the following criteria. </p> <p> <ul id="CD009403-list-0008"> <li> <p>Ethnicity of participants</p> </li> <li> <p>Microalbuminuria or macroalbuminuria</p> </li> <li> <p>Participants with or without hypertension, dyslipidaemia, or abnormal blood glucose</p> </li> <li> <p>Treatment duration (&lt; 6 months or ≥ 6 months)</p> </li> <li> <p>Different combinations of vitamin B derivatives</p> </li> <li> <p>Dose</p> </li> <li> <p>Use of ACEi or ARB or both</p> </li> <li> <p>Use of other antihypertensive treatments.</p> </li> </ul> </p> </section> <section id="CD009403-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>Due to insufficient studies, we were not able to perform sensitivity analysis as planned to explore the influence of the following factors on effect size. </p> <p> <ul id="CD009403-list-0009"> <li> <p>Repeating the analysis excluding unpublished studies</p> </li> <li> <p>Repeating the analysis taking into account risk of bias, as specified</p> </li> <li> <p>Repeating the analysis excluding very long or large studies to establish how much they dominate the results </p> </li> <li> <p>Repeating the analysis excluding studies to filter: diagnostic criteria, language of publication, source of funding (industry versus other), and country. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009403-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009403-sec-0054"></div> <section id="CD009403-sec-0055"> <h3 class="title">Description of studies</h3> <section id="CD009403-sec-0056"> <h4 class="title">Results of the search</h4> <p>See <a href="./references#CD009403-sec-0117" title="">Characteristics of included studies</a> and <a href="./references#CD009403-sec-0118" title="">Characteristics of excluded studies</a> for full details of the studies. </p> <p>We identified a total of 91 records (60 studies) after running the search strategy in Cochrane Renal Group's Specialised Register through contact with the Trials' Search Co‐ordinator. The search resulted in a unique list of references in which studies with multiple publications were linked through a common identifier. </p> <p>We excluded a total of 50 studies (76 articles) based on titles or abstracts which were not relevant to our review. We included nine studies (14 records) for this review (<a href="#CD009403-fig-0001">Figure 1</a>). There was a complete agreement in study selection process between the two authors. </p> <div class="figure" id="CD009403-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009403-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>One study, listed in ClinicalTrials.gov, is awaiting assessment (<a href="./references#CD009403-sec-0119" title="">Characteristics of studies awaiting classification</a>). This study evaluated the effects of folic acid in patients with DKD. We found neither a full publication nor any conference abstracts for this study. We were unable to get any data upon contacting the authors, we will incorporate this study as and when results are publicly available. </p> </section> <section id="CD009403-sec-0057"> <h4 class="title">Included studies</h4> <p>We included nine studies enrolling 1354 participants (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>; <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>). All were published in English and all were parallel group designs. </p> <section id="CD009403-sec-0058"> <h5 class="title">Number of study centres, countries, locations and settings</h5> <p>Four studies were carried out in a single centre at a diabetic outpatient clinic; two in Pakistan (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>), one in the Netherlands (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>), and one in UK (<a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>). Five were multicentre studies. <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> was carried out at five different university medical centres in Canada. Four studies (<a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) were international studies carried out in Australia, Canada, Belgium, Israel, South Africa, UK, and USA. </p> </section> <section id="CD009403-sec-0059"> <h5 class="title">Duration of intervention</h5> <p>Duration of intervention varied from two months (<a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>), three months (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>), six months (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>); 12 months (<a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>), and 36 months (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>). </p> </section> <section id="CD009403-sec-0060"> <h5 class="title">Participants</h5> <p>Nine studies compared 1354 participants randomised to either vitamin B and its derivatives or placebo or active control. A total of 1102 participants were randomised to single vitamin B derivatives, placebo or active control in eight studies, and 252 participants randomised to multiple vitamin B derivatives or placebo. </p> <section id="CD009403-sec-0061"> <h6 class="title">Inclusion criteria</h6> <p>All the studies included patients with DKD, however, the diagnostic criteria and severity of DKD varied across the studies. Three studies (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>) included patients with initial stages of DKD. <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a> included patients with UAE ranging from 15 to 300 mg/24 h or equivalent albumin:creatinine ratio (ACR) (males: 1.25 to 25 mg/mmol; females: 1.75 to 35 mg/mmol) in two of three samples despite ACEIs or ARBs, or both in unchanged dose for at least three months. <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a> and <a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a> defined microalbuminuria as UAE 30 to 299 mg/24 h urine. Five studies (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) included advanced stages of DKD. Four studies (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) defined DKD as clinical or histological diagnosis of DKD, and UAE at least of 300 mg/d or urinary protein level of at least 500 mg/24 h; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a> defined DKD as a SCR of 1.3 to 3.3 mg/dL (women) or 1.5 to 3.5 mg/dL (men), and 24 hour urine ACR ratio &gt; 1200 mg/g while receiving an ACEis or ARBs at the maximum Food and Drug Administration recommended dosage for more than three months. Two studies included participants as per levels of their SCr ≤ 2.0 mg/dL (<a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>) and 2.1 to 3.5 mg/dL in <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>. <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a> defined DKD as an ACR &gt; 2.5 mg/mmol in men and &gt; 3.5 mg/mmol in women in a minimum of two of three early morning urine samples taken on separate days over a period of three months. </p> <p>Three studies (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>) mentioned inclusion of only type 2 diabetes patients, four studies (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) included both type 1 and type 2 diabetes patients, and <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a> included only patients with type 1 diabetes. </p> </section> <section id="CD009403-sec-0062"> <h6 class="title">Exclusion criteria</h6> <p>Exclusion criteria among the included studies consisted of followings: significant diseases such as advance stage of kidney disease like ESKD; patients on dialysis or imminently expected to require dialysis; kidney insufficiency; kidney impairment by causes other than diabetes; other known kidney disease that may impact on progression rate such as renal artery stenosis or glomerular kidney disease such as membranous nephropathy; liver or kidney disorders; pregnant or lactating women; women of childbearing potential unwilling to practice a form of birth control for the duration of the study, in all of the included studies. Two studies (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>) also excluded patients with cancer and another two studies (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>) excluded patients with hypersensitivity to thiamine. </p> </section> <section id="CD009403-sec-0063"> <h6 class="title">Co‐morbidities and co‐medications</h6> <p>Five studies (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) included patients with stable doses of ACEi or ARB or both in an unchanged dose for at least three months with DKD. In addition, <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> mentioned the use of antihypertensives, antiplatelets, antihyperglycaemic drugs in baseline as co‐medications. <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a> also mentioned use of insulin, hypoglycaemic agents (sulphonylureas, metformin, thiazolidinedione), antihypertensive drugs, cholesterol lowering drugs among the participants. </p> </section> </section> <section id="CD009403-sec-0064"> <h5 class="title">Interventions and comparisons</h5> <p>Eight studies (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>; <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>) compared monotherapy of vitamin B preparations with placebo or active control. All interventions and controls were given orally. </p> <p> <ul id="CD009403-list-0010"> <li> <p>Benfotiamine: 900 mg/d (300 mg three times/d) versus placebo (once daily) (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>) </p> </li> <li> <p>Folic acid: 5 mg (once daily) versus placebo (<a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>) </p> </li> <li> <p>Pyridoxamine: 100 mg/d (50 mg twice daily) versus placebo (<a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>). </p> </li> <li> <p>Pyridoxamine: 300 mg/d, (150 mg twice daily) versus placebo (<a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>) </p> </li> <li> <p>Pyridoxamine: 500 mg/d (250 mg twice daily) versus placebo in two clinical studies (<a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) </p> </li> <li> <p>Pyridoxamine: 600 mg/d (300 mg twice daily) versus placebo (twice daily) (<a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>) </p> </li> <li> <p>Thiamine: 300 mg/d, (three 100 mg capsules of thiamine) versus placebo (once daily) (<a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>) </p> </li> <li> <p>Vitamin B<sub>12</sub>: 500 µg/d (once daily) versus losartan 50 mg/d (once daily) (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>) </p> </li> </ul> </p> <p>One study compared oral combined vitamin B therapy with placebo</p> <p> <ul id="CD009403-list-0011"> <li> <p>Vitamin B tablets containing 2.5 mg of folic acid, 25 mg of vitamin B<sub>6</sub>, and 1 mg vitamin B<sub>12</sub> (once daily) versus matching placebo (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>) </p> </li> </ul> </p> <p>None of the studies disclosed the contents of the placebo.</p> </section> <section id="CD009403-sec-0065"> <h5 class="title">Reported outcomes</h5> <p>Three studies (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>) measured change from baseline in UAE as a primary outcome while <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> considered it under secondary outcomes. Change from baseline in SCr was a primary outcome in four studies (<a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>). In addition, <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a> also measured Kidney Injury Molecule‐1 as a primary outcome. Secondary outcomes in <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a> were change in urinary excretion of B<sub>2</sub> microglobulin, macrophage inhibiting factors, and other AGE products. <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> assessed kidney outcomes such as CrCl and progression to dialysis; vascular events such as stroke and death, and decline in cognitive function. <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a> measured plasma cholesterol profile as a secondary outcome. None of the studies reported quality of life or cost as outcomes. <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a> assessed plasma homocysteine, forearm blood flow, total antioxidant status, and whole blood glutathione. </p> </section> <section id="CD009403-sec-0066"> <h5 class="title">Baseline characteristics</h5> <p>All the studies reported basic demographic, biochemical and clinical parameters compared at baseline. The number of patients ranged from 40 to 361 patients. Six studies (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) had higher proportion of male participants compared to female, while <a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a> and <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a> had roughly equal proportions of male and female participants. <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> included the patients with median duration of microalbuminuria of two years (interquartile range (IQR) = 3 years), while <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a> included the patients with mean duration of DKD of approximately five years. <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> had the highest UAE (maximum median 900 (IQR = 150) mg/24 h) in control group. Three studies (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>) included significantly higher proportion of patients with microalbuminuria. </p> </section> </section> <section id="CD009403-sec-0067"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 45 RCTs that did not assess the intervention in the population of our interest for the review. These studies included participants with established ESKD. Four studies were not randomised, and one study (<a href="./references#CD009403-bbs2-0052" title="Spoelstra‐deMA , BrouwerCB , TerheggenF , BollenJM , StehouwerCD , SmuldersYM . No effect of folic acid on markers of endothelial dysfunction or inflammation in patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia. Netherlands Journal of Medicine2004;62(7):246‐53. [MEDLINE: 15554600] ">Spoelstra 2004</a>) was excluded as it assessed the effects of folic acid in patients with diabetes not having DKD. </p> </section> </section> <section id="CD009403-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD009403-fig-0002">Figure 2</a> and <a href="#CD009403-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD009403-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009403-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009403-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009403-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>Interrater agreement for the key quality indicators such as randomisation, concealment of allocation and blinding was complete with no full publication needing to be discussed with a third author. </p> <section id="CD009403-sec-0069"> <h4 class="title">Allocation</h4> <p>Six studies (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) were at low risk of selection bias related to random sequence generation and allocation concealment as participant allocation was conducted remotely or used sealed opaque envelopes. Three studies (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>) were unclear with respect to the risk of selection bias related to sequence generation and allocation, as the methods used were not clearly described. </p> </section> <section id="CD009403-sec-0070"> <h4 class="title">Blinding</h4> <p><a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a> was single blind study with high risk of detection or performance bias while other included studies were double blind studies. <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>, <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; and <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a> were at low risk for performance bias provided the blinding condition at patient, caregiver and observer level with blinding of serum vitamin level in follow‐up. <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> was at low risk of performance and detection bias while five studies (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>; <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>) were judged as having unclear risk for performance bias and detection bias related to blinding, as the method used was not clearly described and did not report checking of blinding conditions. It was not confirmed whether any precaution was taken for blinding lab data of vitamin status (thiamine level) in the follow‐up and endpoint evaluation in those published clinical study reports. </p> </section> <section id="CD009403-sec-0071"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> had a high risk of attrition bias. For clinical outcomes such as mortality, intention‐to‐treat analysis with 94% of randomised participant was utilised. A total of 87%, 81%, 68% and 47% of randomised participants were available for assessing biochemical outcomes at the end of 12, 18, 24 and 36 months respectively. <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> used multiple imputation techniques for missing variables. There was insufficient information available for <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a> (unclear risk of bias) and all other studies were judged to be at low risk of bias. </p> </section> <section id="CD009403-sec-0072"> <h4 class="title">Selective reporting</h4> <p>Seven studies had low risk of reporting bias based on comparison of reported outcomes in the protocol and final publication. The protocols were not available for two studies (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>). </p> <section id="CD009403-sec-0073"> <h5 class="title">Publication and small study bias</h5> <p>No clear interpretation of the funnel plot was possible because of relatively small number of included studies. </p> </section> </section> <section id="CD009403-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>Four studies funded by pharmaceutical companies were judged to be at high risk bias, three were at low risk of bias, and two were unclear. </p> </section> </section> <section id="CD009403-sec-0075"> <h3 class="title" id="CD009403-sec-0075">Effects of interventions</h3> <p>We presented summary of results for reported outcomes of the available studies. <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a> did not assess any of the outcomes prespecified in review. </p> <section id="CD009403-sec-0076"> <h4 class="title">Vitamin B versus placebo</h4> <p>Seven studies (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>) compared monotherapy versus placebo or active treatment. Three studies (<a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) presented the results of those studies in a single publication with combining data from two phase studies and a separate abstract for one study. The authors combined the data from individual studies to increase the sample size. </p> <section id="CD009403-sec-0077"> <h5 class="title">Primary outcomes</h5> <section id="CD009403-sec-0078"> <h6 class="title">All‐cause mortality</h6> <p>Five studies reported all‐cause mortality (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) </p> <p>Four studies (<a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) reported all‐cause mortality with different doses of pyridoxamine monotherapy. There was no significant difference in risk of mortality with use of any dose or duration of pyridoxamine compared to placebo (<a href="./references#CD009403-fig-0004" title="">Analysis 1.1</a>) (100 mg/d for 6 months (1 study, 128 participants): RR 2.91, 95% CI 012 to 70.10; 300 mg/d for 12 months (1 study, 202 participants): RR 2.60, 95% CI 0.522 to 13.10; 500 mg/d for 5 months (1 study, 84 participants): RR 3.38, 95% CI 0.18 to 63.2; 600 mg/d for 12 months (1 study, 208 participants): RR 0.49, 95% CI 0.05 to 5.33). </p> <p><a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> reported no significant difference in all‐cause mortality with the use of combined therapy versus placebo for three years (1 study; 238 participants: RR 0.86, 95% CI 0.30 to 2.48). </p> </section> <section id="CD009403-sec-0079"> <h6 class="title">Cardiovascular mortality</h6> <p>No study reported cardiovascular mortality.</p> </section> </section> <section id="CD009403-sec-0080"> <h5 class="title">Secondary outcomes</h5> <section id="CD009403-sec-0081"> <h6 class="title">Creatinine clearance</h6> <p>Six studies (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) measured CrCl, however data were only available from <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>. </p> <p><a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a> reported no significant difference in CrCl at the end of three months between benfotiamine and placebo (<a href="./references#CD009403-fig-0005" title="">Analysis 1.2</a> (1 study, 82 participants): MD 2.00 mL/min, 95% CI ‐21.78 to 25.78). </p> <p>Four studies (<a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) reported no significant effects of pyridoxamine on improving CrCl compared to placebo. </p> <p><a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> reported no significant difference in CrCl with combined vitamin B therapy compared to placebo. </p> </section> <section id="CD009403-sec-0082"> <h6 class="title">Serum creatinine</h6> <p>Seven studies measured SCr (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>), however <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> and <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a> did not report their results. </p> <p><a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a> reported no difference in SCr following three months of benfotiamine compared to placebo (<a href="./references#CD009403-fig-0006" title="">Analysis 1.3</a>.1 (82 participants): MD 1.00 µmol/L, 95% CI ‐7.88 to 9.88). <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a> reported no significant change in SCr with either 300 mg/d (<a href="./references#CD009403-fig-0006" title="">Analysis 1.3</a>.2 (150 participants): MD 5.33 µmol/L, 95% CI ‐6.02 to 16.68) or 600 mg (<a href="./references#CD009403-fig-0006" title="">Analysis 1.3</a>.3 (157 participants): MD 0.02 µmol/L, 95% CI ‐11.05 to 11.09) pyridoxamine for 12 months. <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>, <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a> and <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a> did not find any significant change in the SCr in the pooled estimate from all their studies (<a href="./references#CD009403-fig-0006" title="">Analysis 1.3</a>.4 (212 participants): MD ‐8.84 µmol/L, 95% CI ‐20.21 to 2.53). </p> </section> <section id="CD009403-sec-0083"> <h6 class="title">Proteinuria</h6> <p>Five studies (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) measured proteinuria, however, only two studies provided data (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>). </p> <p><a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> reported no significant difference in the level of proteinuria after three years of combined vitamin B therapy compared to placebo (<a href="./references#CD009403-fig-0007" title="">Analysis 1.4</a>.1 (118 participants): MD: 0.05 g/24 h, 95% CI ‐0.39 to 0.49). <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a> reported no significant difference in proteinuria with pyridoxamine 300 mg/d (<a href="./references#CD009403-fig-0007" title="">Analysis 1.4</a>.2 (202 participants): MD ‐0.00 g/24 h, 95% CI ‐0.04 to 0.05); however there was a significant decrease in proteinuria in the 600 mg/d pyridoxamine group compared to placebo (<a href="./references#CD009403-fig-0007" title="">Analysis 1.4</a>.3 (208 participants): MD: ‐0.30 g/dL, 95% CI ‐0.34 to 0.25). </p> </section> <section id="CD009403-sec-0084"> <h6 class="title">Urinary albumin excretion</h6> <p>Seven studies (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>) measured UAE. None of the studies reported the data that could be meta‐analysed. </p> <p><a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a> reported a significant median reduction in UAE with thiamine treatment compared to placebo. The remaining studies did not find a significant reduction in UAE with either pyridoxamine, benfotiamine, or combined vitamin B therapy. </p> </section> <section id="CD009403-sec-0085"> <h6 class="title">Glomerular filtration rate</h6> <p>Seven studies measured GFR (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>), however <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>, <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>, <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a> and <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a> did not report their results. </p> <p><a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> reported a significant reduction in GFR with combined vitamin B therapy compared to placebo (<a href="./references#CD009403-fig-0008" title="">Analysis 1.5</a>.1: MD ‐5.80 mL/min/1.73 m², 95% CI ‐10.51 to ‐1.10). <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a> reported no significant change in GFR with pyridoxamine (MD 0.36 mL/min/1.73 m², 95% CI ‐5.25 to 5.97), and <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a> found no significant change in GFR with thiamine (MD 0.31 mL/min, 95% CI ‐4.51 to 5.13) when compared to placebo. </p> </section> <section id="CD009403-sec-0086"> <h6 class="title">Number of patients required dialysis</h6> <p><a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> reported no significant change in the risk of dialysis requirement with combined vitamin B therapy (<a href="./references#CD009403-fig-0009" title="">Analysis 1.6</a> (238 participants): RR 1.00, 95% CI 0.43 to 2.31) compared to placebo. </p> </section> <section id="CD009403-sec-0087"> <h6 class="title">Blood pressure</h6> <p>Six studies (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>) measured blood pressure as an outcome, however data were not presented for three studies (<a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>). </p> <p><a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a> reported no significant difference SBP after 12 weeks of treatment with benfotiamine (<a href="./references#CD009403-fig-0010" title="">Analysis 1.7</a>.1 (82 participants): MD 3.00 mm Hg, 95% CI ‐4.37 to 10.37). <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> reported no significant change in the SBP with combined vitamin B therapy for 36 months (<a href="./references#CD009403-fig-0010" title="">Analysis 1.7</a>.2 (118 participants): MD 2.30 mm Hg, 95% CI ‐3.70 to 8.30) compared to placebo. <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a> reported no change in SBP with thiamine given for 12 weeks (<a href="./references#CD009403-fig-0010" title="">Analysis 1.7</a>.3 (40 participants): MD 3.00 mm Hg, 95% CI ‐8.50 to 14.50) compared to placebo. </p> <p><a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a> reported no significant change in DBP after 12 weeks of treatment with benfotiamine (<a href="./references#CD009403-fig-0011" title="">Analysis 1.8</a>.1 (82 participants): MD: 0.00, 95% CI ‐4.11 to 4.11). <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> reported no significant change in the DBP with combined vitamin B therapy for 36 months (<a href="./references#CD009403-fig-0011" title="">Analysis 1.8</a> (118 participants): MD 1.50, 95% CI ‐1.60 to 4.60) compared to placebo. <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a> reported no change in DBP with thiamine for 12 weeks (<a href="./references#CD009403-fig-0011" title="">Analysis 1.8</a>.3 (40 participants): MD 1.00, 95% CI ‐4.28 to 6.28). </p> </section> <section id="CD009403-sec-0088"> <h6 class="title">Adverse events</h6> <p>Studies of less than six months duration did not explicitly report adverse events. They all reported that the drugs were well‐tolerated without any serious drug related adverse events. </p> <p>Five studies (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>) reported the adverse event profile in detail. <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> reported a total of 1060 adverse events (535 in the placebo group and 525 in the B vitamin group); these included many transient minor complaints, such as dizziness, nausea, or headache. <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a> reported 49 (46.7%) severe adverse events in the placebo group, 41 (39.4%) occurred in the pyridoxamine 150 group, and 42 (40%) occurred in the pyridoxamine 300 mg group. Data for two separate studies of pyridoxamine 500 mg/d and placebo were combined and compared by the authors (<a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>); we combined the 300 mg/d and 600 mg/d data from <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>. No study reported significant differences in adverse events or in any serious or severe adverse events between vitamin B treatments and placebo (<a href="./references#CD009403-fig-0012" title="">Analysis 1.9</a>). </p> </section> </section> </section> <section id="CD009403-sec-0089"> <h4 class="title">Vitamin B versus other substances</h4> <p><a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a> compared Vitamin B<sub>12</sub> (mecobalamin) versus losartan (ARB; active control). </p> <section id="CD009403-sec-0090"> <h5 class="title">Primary outcomes</h5> <p>All‐cause mortality and cardiovascular morality were not reported.</p> </section> <section id="CD009403-sec-0091"> <h5 class="title">Secondary outcomes</h5> <section id="CD009403-sec-0092"> <h6 class="title">Serum creatinine</h6> <p><a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a> reported no significant difference in SCr levels between the vitamin B<sub>12</sub> and losartan groups (<a href="./references#CD009403-fig-0016" title="">Analysis 2.1</a> (261 participants): MD 0.00 mg/dL, 95% CI ‐0.09 to 0.09). </p> </section> <section id="CD009403-sec-0093"> <h6 class="title">Urinary albumin excretion</h6> <p><a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a> reported no significant difference in UAE levels between the vitamin B<sub>12</sub> and losartan groups (<a href="./references#CD009403-fig-0017" title="">Analysis 2.2</a> (261 participants): MD 56.40 mg/dL, 95% CI 52.61 to 60.19). </p> </section> <section id="CD009403-sec-0094"> <h6 class="title">Blood pressure</h6> <p><a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a> reported a significant increase in SBP in the vitamin B<sub>12</sub> group (<a href="./references#CD009403-fig-0018" title="">Analysis 2.3</a> (261 participants): MD 3.00 mm Hg, 95% CI 0.63 to 5.37). </p> <p><a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a> reported a significant increase in DBP in the vitamin B<sub>12</sub> group (<a href="./references#CD009403-fig-0019" title="">Analysis 2.4</a> (261 participants): MD 2.70 mm Hg, 95% CI 0.29 to 5.11). </p> </section> </section> </section> <section id="CD009403-sec-0095"> <h4 class="title">Other outcomes</h4> <p>None of the included studies reported the following outcomes: progression from macroalbuminuria to ESKD, progression from microalbuminuria to macroalbuminuria, regression from microalbuminuria to normoalbuminuria, doubling of SCr, and quality of life. We were not able to perform subgroup or sensitivity analyses or assess publication bias due to insufficient data. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009403-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009403-sec-0096">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009403-sec-0137">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009403-sec-0096"></div> <section id="CD009403-sec-0097"> <h3 class="title" id="CD009403-sec-0097">Summary of main results</h3> <p>The review aimed to assess the effects of vitamin B therapy on various clinical and biochemical outcomes in patients with DKD. Nine studies (2560 participants) meet our inclusion criteria. Eight studies (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>) assessed vitamin B or its derivatives versus placebo in patients with DKD (benfotiamine (300 mg/d), thiamine (300 mg/d), vitamin B<sub>12</sub> (500 mg/d), pyridoxamine (100 mg/d, 300 mg/d, 600 mg/d), folic acid (5 mg/d)); one study (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>) compared vitamin B with an active control (vitamin B<sub>12</sub> versus losartan); and one study (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>) compared combined vitamin B therapy (folic acid: 2.5 mg; vitamin B<sub>6</sub>: 25 mg; vitamin B<sub>12</sub>: 1 mg) with placebo. Treatment duration ranged from two to 36 months. </p> <p>We found that there was no difference in the risk of all‐cause of mortality with pyridoxamine at doses of 100 mg/d, 300 mg/d, 500 mg/d, or 600 mg/d dose for five to 12 months of treatment compared to placebo (<a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>). None of the derivatives improved kidney functions such as increase in CrCl or GFR. Only one study reported improvement in UAE with thiamine (<a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>). None of the included studies reported outcomes such cardiovascular mortality, progression from macroalbuminuria to ESKD, progression from microalbuminuria to macroalbuminuria, regression from microalbuminuria to normoalbuminuria, number of patients requiring dialysis, quality of life parameters and cost. </p> <p><a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> reported no significant difference in the risk of mortality with combined vitamin B therapy; conversely, the authors reported an increase in risk of MI, stroke, revascularization, and all‐cause mortality, in the B vitamin group after adjusting for baseline risk factors including peripheral vascular disease. Further, <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> reported a reduction in GFR following the use of vitamin B therapy. The combined vitamin B therapy neither significantly increased CrCl nor decreased the level of UAE. In addition, there were no additional benefits in reducing the risk of dialysis requirement with the combined vitamin B therapy. There was no significant difference between combined vitamin B group and placebo for adverse events. <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a> did not report outcomes such as progression from macroalbuminuria to ESKD, progression from microalbuminuria to macroalbuminuria, regression from microalbuminuria to normoalbuminuria, CrCl, doubling of SCr, SCr, SBP, DBP, quality of life, and cost. </p> </section> <section id="CD009403-sec-0098"> <h3 class="title" id="CD009403-sec-0098">Overall completeness and applicability of evidence</h3> <p>The number of patients per study ranged from 16 to 361 and the age range was 40 to 75 years. We found different populations across studies, i.e. studies performed in Asian settings included higher proportion of patients with microalbuminuria while two studies only enrolled patients with macroalbuminuria. There was a significant difference in baseline SBP, DBP, and cholesterol levels among the studies. These risk factors were different among studies for diabetic complications however they did not differ within studies. The definition of microalbuminuria varied across studies. We were unable to perform the sensitivity analysis for diagnosis or severity of DKD due to the limited number of studies identified. Despite this limitation, results across the studies were consistent for any of the clinical or biochemical outcomes. We did not find any data on outcome measurements such as time to ESKD, and only limited data on all‐cause mortality. The reason may be such outcomes are difficult to implement on a practical basis. However, the considering slow disease progression of DKD, it would be difficult to extrapolate results of short duration changes on long‐term clinical outcomes. A systematic review found that increase in GFR and reduction in albuminuria were associated with lower mortality in advance kidney disease (<a href="./references#CD009403-bbs2-0074" title="BerhaneAM , WeilEJ , KnowlerWC , NelsonRG , HansonRL . Albuminuria and estimated glomerular filtration rate as predictors of diabetic end‐stage renal disease and death. Clinical Journal of The American Society of Nephrology: CJASN2011;6(10):2444‐51. [MEDLINE: 21852671] ">Berhane 2011</a>). We found that only one study with thiamine improved the albuminuria level compared to placebo. The remaining eight studies showed no improvement in GFR and albuminuria. </p> <p>In the included studies, one of the major sources which would vary the actual amount of vitamin B intake is the dietary sources of vitamin B. Vitamin B can be obtained through various dietary sources, fortified foods etc. Majority of the studies did not ask the participants to change their diet habits in both of the group in individual studies. There is a high likelihood that the dietary source of vitamin B would be different among studies as dietary food habits across the countries vary widely. Asian, American, Canadian and European people have different food habits. In addition, food fortification programme has been implemented in the US and Canada. Hence, the participants for these countries may have higher level of vitamins. </p> <p>Ethnicity/race is an important determinant of folate status under conditions of strictly controlled dietary folate intake (<a href="./references#CD009403-bbs2-0116" title="PerryCA , RennaSA , KhitunE , OrtizM , MoriartyDJ , CaudillMA . Ethnicity and race influence the folate status response to controlled folate intakes in young women. Journal of Nutrition2004;134(7):1786‐92. [MEDLINE: 15226470] ">Perry 2004</a>). Due to limited number of the studies, we were not able to perform subgroup analysis for a priori ethnicity subgroup. Other source of vitamin B and racial variation should be taken into consideration while designing future studies. One of the way to handle this confounding issue is to baseline monitoring of these vitamin B derivatives. In addition, urinary excretion of thiamine &gt; 0.20 µmol/24 h indicates adequate dietary thiamine for adults (<a href="./references#CD009403-bbs2-0087" title="FinglasPM . Thiamin. International Journal for Vitamin &amp; Nutrition Research1993;63(4):270‐4. [MEDLINE: 8157433] ">Finglas 1993</a>). So, the level of such markers of adequate dietary thiamine sufficiency could serve as control parameter for dietary intake. The level of this vitamin at baseline would be an important criterion to consider for inclusion. </p> </section> <section id="CD009403-sec-0099"> <h3 class="title" id="CD009403-sec-0099">Quality of the evidence</h3> <p>Minimising the risk of bias is of major importance for a good quality systematic review. In this review, we therefore restricted the meta‐analysis to RCTs, ideally with proper randomisation, allocation concealment, blinding and freedom from selective reporting. However, not all the studies fulfilled this criteria. Three studies (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>) did not clearly report the methods used for sequence generation and allocation (selection bias) and were judge to have unclear risk of bias. The remaining six studies were at low risk of selection bias (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>). Two studies (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>) reported blinding of patient, caregiver and observer and were at low risk of performance and detection bias. Two studies were at high risk of performance and detection bias (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>) and the other five studies had unclear risk of performance bias and detection bias (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>). Attrition bias was high in one study (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>), unclear in one study (<a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>) and low in seven studies (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>). Reporting bias was high in one study (<a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>), unclear in one study (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>) and low in the remaining seven studies (<a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>). Four studies funded by pharmaceutical companies were judged to be at high risk bias (<a href="./references#CD009403-bbs2-0004" title="LewisEJ , GreeneT , SpitalewizS , BlumenthalS , BerlT , HunsickerLG , et al. Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology2012;23(1):131‐6. [MEDLINE: 22034637] ">Lewis 2012</a>; <a href="./references#CD009403-bbs2-0005" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐205 Study 2007</a>; <a href="./references#CD009403-bbs2-0006" title="BellDS , DegenhardtTP , SzaboJR , KhalifahRG , SchotzingerRJ , PYR‐206 Study Group. Investigation of the safety and efficacy of pyridoxamine (Pyridorin) in patients with diabetic nephropathy (PYR‐206) [abstract]. Diabetes2004;53(Suppl 2):A119. WassenbergJJ , KnightST , FoxJW , DegenhardtTP , SzaboJ , KhalifahRG . The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in diabetic patients with overt nephropathy [abstract no: SA‐PO451]. Journal of the American Society of Nephrology2003;14(Nov):395A. WilliamsME , BoltonWK , DegenhardtTP , SchotzingerR . A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR‐206) [abstract no: F‐FC029]. Journal of the American Society of Nephrology2003;14(Nov):7A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐206 Study 2007</a>; <a href="./references#CD009403-bbs2-0007" title="McGillJB , WilliamsME , DegenhardtTP , SzaboJR , SchotzingerRJ , PYR‐205/207 Study Group. A phase 2 clinical investigation of pyridoxamine (Pyridorim™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR‐205/207) [abstract no: SU‐PO152]. Journal of the American Society of Nephrology2004;15(Oct):565A. WassenbergJJ , FoxW , DegenhardtTP , SzaboJ , KhalifahRG . Pyridoxamine (Pyridorin™) reduces urinary TGF‐b1 in Phase 2 clinical studies (PYR‐205/207) on Type 1 and Type 2 diabetic patients with overt nephropathy [abstract no: SU‐PO914]. Journal of the American Society of Nephrology2004;15(Oct):729A. WilliamsME , BoltonWK , KhalifahRG , DegenhardtTP , SchotzingerRJ , McGillJB . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. American Journal of Nephrology2007;27(6):605‐14. [MEDLINE: 17823506] ">PYR‐207 Study 2007</a>), three were at low risk of bias (<a href="./references#CD009403-bbs2-0001" title="AghaA , AmerW , AnwarE , BashirK . Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):429‐35. [MEDLINE: 19414946] ">Agha 2009</a>; <a href="./references#CD009403-bbs2-0002" title="AlkhalafA , KloosterA , vanOeverenW , AchenbachU , KleefstraN , SlingerlandRJ , et al. A double‐blind, randomized, placebo‐controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care2010;33(7):1598‐601. [MEDLINE: 20413516] ">Alkhalaf 2010</a>; <a href="./references#CD009403-bbs2-0008" title="RabbaniN , AlamSS , RiazS , LarkinJR , AkhtarMW , ShafiT , et al. High‐dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double‐blind placebo‐controlled pilot study. Diabetologia2009;52(2):208‐12. [MEDLINE: 19057893] ">Rabbani 2009</a>), and two were unclear (<a href="./references#CD009403-bbs2-0003" title="HouseAA , EhasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA‐FC343]. Journal of the American Society of Nephrology2009;20:80A. [CENTRAL: CN‐00740523] HouseAA , EliasziwM , CattranDC , ChurchillDN , OliverMJ , FineA , et al. Effect of B‐vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010;303(16):1603‐9. [MEDLINE: 20424250] ">DIVINe Study 2010</a>; <a href="./references#CD009403-bbs2-0009" title="WotherspoonF , LaightDW , TurnerC , MeekingDR , AllardSE , MundayLJ , et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. International Journal of Clinical Practice2008;62(4):569‐74. [MEDLINE: 18248393] ">Wotherspoon 2008</a>). </p> </section> <section id="CD009403-sec-0100"> <h3 class="title" id="CD009403-sec-0100">Potential biases in the review process</h3> <p>We found many large scale studies performed in diabetic patients especially the <a href="./references#CD009403-bbs2-0029" title="LonnE , YusufS , ArnoldMJ , SheridanP , PogueJ , MicksM , et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. New England Journal of Medicine2006;354(15):1567‐77. [MEDLINE: 16531613] MannJF , SheridanP , McQueenMJ , HeldC , ArnoldJM , FodorG , et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease‐‐results of the renal Hope‐2 study. Nephrology Dialysis Transplantation2008;23(2):645‐53. [MEDLINE: 18003666] RayJG , KearonC , YiQ , SheridanP , LonnE , Heart Outcomes Prevention Evaluation (HOPE‐2) Investigators. Homocysteine‐lowering therapy and risk for venous thromboembolism: a randomized trial. Annals of Internal Medicine2007;146(11):761‐7. [MEDLINE: 17470822] RighettiM . Hopeful for a second HOPE‐2 post hoc analysis. Nephrology Dialysis Transplantation2008;23(7):2428‐9. [MEDLINE: 18403437] SaposnikG , RayJG , SheridanP , McQueenM , LonnE , Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine‐lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke2009;40(4):1365‐72. [MEDLINE: 19228852] SawkaAM , RayJG , YiQ , JosseRG , LonnE . Randomized clinical trial of homocysteine level lowering therapy and fractures. Archives of Internal Medicine2007;167(19):2136‐9. [MEDLINE: 17954810] ">HOPE‐2 Study 2006</a>, and there may be a significant proportion of patients with DKD. However, we had to exclude those studies to remove misclassification bias in the review. It has been demonstrated from observational studies that blood pressure control or blood glucose control also prevents or reverses microalbuminuria (<a href="./references#CD009403-bbs2-0066" title="ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ">ADVANCE 2008</a>). None of the clinical studies addressed the issues of these underlying confounders. </p> </section> <section id="CD009403-sec-0101"> <h3 class="title" id="CD009403-sec-0101">Agreements and disagreements with other studies or reviews</h3> <p>As far as we could ascertain, this is the first systematic review investigating vitamin B therapy for DKD. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009403-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009403-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/full#CD009403-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009403-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/full#CD009403-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009403-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/full#CD009403-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin B versus placebo, Outcome 1 All‐cause mortality." data-id="CD009403-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Vitamin B versus placebo, Outcome 1 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin B versus placebo, Outcome 2 Creatinine clearance." data-id="CD009403-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Vitamin B versus placebo, Outcome 2 Creatinine clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin B versus placebo, Outcome 3 Serum creatinine." data-id="CD009403-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Vitamin B versus placebo, Outcome 3 Serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin B versus placebo, Outcome 4 Proteinuria." data-id="CD009403-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Vitamin B versus placebo, Outcome 4 Proteinuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin B versus placebo, Outcome 5 GFR." data-id="CD009403-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Vitamin B versus placebo, Outcome 5 GFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin B versus placebo, Outcome 6 Patients requiring dialysis." data-id="CD009403-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Vitamin B versus placebo, Outcome 6 Patients requiring dialysis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin B versus placebo, Outcome 7 Systolic blood pressure." data-id="CD009403-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Vitamin B versus placebo, Outcome 7 Systolic blood pressure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin B versus placebo, Outcome 8 Diastolic blood pressure." data-id="CD009403-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Vitamin B versus placebo, Outcome 8 Diastolic blood pressure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin B versus placebo, Outcome 9 One or more adverse events per patient." data-id="CD009403-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Vitamin B versus placebo, Outcome 9 One or more adverse events per patient.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0013"> <p> <div class="table" id="CD009403-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Thiamine</b> </p> <p><b>Baseline; median</b> </p> <p><b>(minimum–maximum)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p><b>Baseline; median</b> </p> <p><b>(minimum–maximum)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Thiamine</b> </p> <p><b>End‐point; median</b> </p> <p><b>(minimum‐maximum)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p><b>End‐point; median</b> </p> <p><b>(minimum‐maximum)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>p‐value; change from baseline</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rabbani 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.7 (33.0–120.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.7 (33.0–120.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.1 (12.0–38.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.5 (6.4–82.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p &lt; 0.01</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Vitamin B versus placebo, Outcome 10 Urinary albumin excretion [mg/24 h]. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0013">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009403-fig-0014"> <p> <div class="table" id="CD009403-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pyridoxamine 100 mg</b> </p> <p><b>Baseline; mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p><b>Baseline; mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pyridoxamine 100 mg</b> </p> <p><b>End‐point; rate of rise/y</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p><b>End‐point; rate of rise/y</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>p‐value</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PYR‐206 Study 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Vitamin B versus placebo, Outcome 11 Serum creatinine [mg/dL].</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0014">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009403-fig-0015"> <p> <div class="table" id="CD009403-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pyridoxamine 100 mg</b> </p> <p><b>Baseline; mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p><b>Baseline; mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pyridoxamine 100 mg</b> </p> <p><b>End‐point; rate of decrease/y</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p><b>End‐point; rate of decrease/yr</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>p‐value</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PYR‐206 Study 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.9 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104.2 (60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p &lt; 0.0001</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Vitamin B versus placebo, Outcome 12 Creatinine clearance [mL/min].</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0015">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009403-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin B versus active control, Outcome 1 Serum creatinine." data-id="CD009403-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Vitamin B versus active control, Outcome 1 Serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin B versus active control, Outcome 2 UAE." data-id="CD009403-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Vitamin B versus active control, Outcome 2 UAE.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin B versus active control, Outcome 3 Systolic blood pressure." data-id="CD009403-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Vitamin B versus active control, Outcome 3 Systolic blood pressure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009403-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/urn:x-wiley:14651858:media:CD009403:CD009403-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_t/tCD009403-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin B versus active control, Outcome 4 Diastolic blood pressure." data-id="CD009403-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Vitamin B versus active control, Outcome 4 Diastolic blood pressure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/media/CDSR/CD009403/image_n/nCD009403-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD009403-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin B versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 PYR 100 mg/d (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 PYR 300 mg/d (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 PYR 500 mg/d (5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 PYR 600 mg/d (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Combined vitamin B therapy (36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Creatinine clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Benfotiamine (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Benfotiamine (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 PYR 300 mg/d (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 PYR 600 mg/d (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 PYR 100/500 mg/d combined data (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proteinuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Combined vitamin B therapy (36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 PYR 300 mg/d (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 PYR 600 mg/d (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 GFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Combined vitamin B therapy (36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 PYR 300 mg/d (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 PYR 600 mg/d (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Thiamine 300 mg/d (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Patients requiring dialysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Combined vitamin B therapy (36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Benfotiamine (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Combined vitamin B therapy (36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Thiamine (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Benfotiamine (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Combined vitamin B therapy (36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Thiamine (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 One or more adverse events per patient <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Urinary albumin excretion [mg/24 h] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Serum creatinine [mg/dL] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Creatinine clearance [mL/min] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin B versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009403-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vitamin B versus active control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Vitamin B12 versus ARB (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 UAE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Vitamin B12 versus ARB (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Vitamin B12 versus ARB (months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Vitamin B12 versus ARB (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vitamin B versus active control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009403.pub2/references#CD009403-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009403.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009403-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009403-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009403-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD009403-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD009403-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD009403-note-0002">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009403\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009403\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009403\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009403\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009403\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009403.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009403.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009403.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009403.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009403.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718439490"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009403.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718439494"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009403.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd05c88bbf401',t:'MTc0MDcxODQzOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 